Get the Stockscreener App
0.5851
7.38%
-0.0466
After Hours:
.57
-0.0151
-2.58%
Calidi Biotherapeutics Inc stock is traded at $0.5851, with a volume of 5.11M.
It is down -7.38% in the last 24 hours and up +161.56% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.6317
Open:
$0.58
24h Volume:
5.11M
Relative Volume:
0.33
Market Cap:
$25.11M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-0.7941
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
-20.85%
1M Performance:
+161.56%
6M Performance:
-6.47%
1Y Performance:
-63.43%
1-Day Range:
$0.564
$0.63
1-Week Range:
$0.5026
$0.91
52-Week Range:
$0.2027
$3.89
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.5851 | 21.81M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics Stock Plunges 10.6% Despite FDA Fast Track Designation - AInvest
Is it too late to sell Calidi Biotherapeutics Inc.AI Screener Based Stock Summary Report - Newser
What risks could impact Calidi Biotherapeutics Inc. stock performanceFree Stock Screener With Smart Filters - Newser
Chart based analysis of Calidi Biotherapeutics Inc. trendsFree Profit Target Stock Opportunity Monitor - Newser
Candlestick signals on Calidi Biotherapeutics Inc. stock todayLong-Term Stock Growth Forecast Insights - Newser
Calidi Biotherapeutics Stock Soars 68% on FDA Fast Track Designation - AInvest
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma - The Manila Times
FDA grants fast track designation to Calidi’s CLD-201 for sarcoma - Investing.com Nigeria
Is Calidi Biotherapeutics Inc. a Top Dividend Stock to Watch in 2025Early Entry Ideas with Momentum Potential - Newser
Calidi Biotherapeutics Inc. Stock Support and Resistance Levels You Should KnowValue Investing Checklist with Entry Signals - Newser
Why Calidi Biotherapeutics Inc. stock attracts strong analyst attentionMarket Ready Picks with Technical Support - Newser
Published on: 2025-07-29 02:14:07 - Newser
Short Covering May Lift Calidi Biotherapeutics Inc. in Near TermAccurate Technical Trend Reversal Picks Detected - metal.it
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics - citybuzz -
Is Calidi Biotherapeutics Inc. stock overvalued or undervaluedPhenomenal wealth increase - jammulinksnews.com
How to forecast Calidi Biotherapeutics Inc. trends using time seriesPrice Action Summary and Entry Strategy Guide - Newser
How to interpret RSI for Calidi Biotherapeutics Inc. stockShort Term Opportunity Finder with Tools - Newser
Why Did Calidi Biotherapeutics Stock Plunge 10.55%? - AInvest
Does Calidi Biotherapeutics Inc. stock perform well during market downturnsRecord-setting profit potential - jammulinksnews.com
What are analysts’ price targets for Calidi Biotherapeutics Inc. in the next 12 monthsMaximize returns with strategic portfolio planning - jammulinksnews.com
How does Calidi Biotherapeutics Inc. compare to its industry peersInvest confidently with professional guidance - jammulinksnews.com
How volatile is Calidi Biotherapeutics Inc. stock compared to the marketHigh-yield market plays - jammulinksnews.com
What makes Calidi Biotherapeutics Inc. stock price move sharplyAccelerated wealth expansion - jammulinksnews.com
Buy Signal for Calidi Biotherapeutics Inc. Stock Key Technical Indicators to WatchSmart Trading With Safety Margin - Newser
Calidi announces reverse stock split, expected to begin trading on a 1-for-12 split adjusted basis - MSN
Calidi announces 1-for-12 reverse stock split - TipRanks
Calidi Biotherapeutics' 1-for-12 Reverse Stock Split: Strategic Rebranding or a Desperate Lifeline? - AInvest
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Enhance Market Appeal - Quiver Quantitative
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - GlobeNewswire
Calidi Biotech Plans Major 1:12 Reverse Split: What Shareholders Must Know Before August 5 - Stock Titan
What analysts say about Calidi Biotherapeutics Inc. stockExplosive returns - PrintWeekIndia
Is Calidi Biotherapeutics Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Is Calidi Biotherapeutics Inc. stock overhyped or has real potentialTriple-digit returns - jammulinksnews.com
What drives Calidi Biotherapeutics Inc. stock priceRapid wealth creation - PrintWeekIndia
Should I buy Calidi Biotherapeutics Inc. stock before earningsExplosive portfolio gains - jammulinksnews.com
Calidi Biotherapeutics Inc. Stock Analysis and ForecastMassive profits - PrintWeekIndia
40-Year Biotech Veteran Jim Schoeneck Joins Connect Biopharma Board as Asthma Drug Enters Critical Phase - Stock Titan
Calidi Biotherapeutics Invites Investors to Webinar on Precision Genetic Medicine Advances - Nasdaq
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24 - GlobeNewswire
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Cap:
|
Volume (24h):